IL20RA (Gene)

Synonyms:CRF2-8, ENTREZ:53832, HGNC:6003, IL-20R-alpha, IL-20R1, IL-20RA, IL20RA, MIM:605620, NM_001278722, NM_001278723, NM_001278724, NM_014432, NP_001265651, NP_001265652, NP_001265653, NP_055247, XM_006715506, XM_011535904, XM_017010954, XM_017010955, XP_006715569, XP_011534206, XP_016866443, XP_016866444, interleukin 20 receptor subunit alpha
Omim:OMIM:605620
Id:ENSG00000016402
Hgnc:HGNC:6003
Entrez:53832
Description:interleukin 20 receptor subunit alpha
This gene encodes a member of the type II cytokine receptor family. The encoded protein is a subunit of the receptor for interleukin 20, a cytokine that may be involved in epidermal function. The interleukin 20 receptor is a heterodimeric complex consisting of the encoded protein and interleukin 20 receptor beta. This gene and interleukin 20 receptor beta are highly expressed in skin, and are upregulated in psoriasis. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2013]

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View IL20RA's neighborhood in the knowledge graph.

Playbook Workflow Builder
Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with IL20RA.

Gene Partnership Appyter
CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using IL20RA.

Gene and Drug Landing Page Aggregator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for IL20RA.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with IL20RA.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.